Business Roundtable
Finance: IPOs and Exit Strategies for Achieving Liquidity. Getting the Money While the Getting is Good.
Wednesday, October 10, 2007
9:10 AM
Telegraph
Most private companies today find themselves actively managing dual exit strategies while simultaneously juggling banker and partner meetings. Investor and industry experts and veterans will describe the key factors, metrics and cultural decisions that are weighed when determining a company's future.
Moderators
- Annette Grimaldi; Managing Director and Head of Life Sciences Investment Banking, Jefferies & Company, Inc.
Panelists
- Scott W. Morrison; Partner, Ernst & Young LLP, US Biotechnology and Medtech Industry Leader
- Graham Cooper; Chief Financial Officer, OREXIGEN Therapeutics, Inc.
- Neil Kurtz, MD; Chief Executive Officer, TorreyPines Therapeutics
- William D. Waddill; Former Chief Financial Officer, Ilypsa Inc.
- Mark B. Weeks; Managing Director, Heller Ehrman LLP
- Matthew Perry; Portfolio Manager, Biotechnology Value Fund, L.P.
Who's Who
Annette Grimaldi has nearly 18 years experience on Wall Street, the majority being focused in healthcare. Prior to Jefferies, she spent nearly 10 years at SG Cowen, where she led that firm's investment banking in the biotech and emerging pharmaceutical sector. Previously, Ms. Grimaldi spent eight years at Goldman Sachs, and has advised companies in connection with raising public and private equity and other strategic transactions. She received a Masters in Business Administration and a Masters in International Studies from The Wharton School at the University of Pennsylvania, and a Bachelor of Science in Foreign Services degree from Georgetown University.
Scott Morrison is Ernst & Young?s U.S. Biotechnology and Medtech practice leader and a member of the global industry group. He has 26 years of local national and global experience serving Biotechnology medical device clients. Scott has served clients in every stage of growth and has helped many companies through the challenges of launching initial products. He has worked on numerous public and private financings, including initial and follow-on offerings. His professional experience includes corporate alliances, spinouts, joint ventures and mergers & acquisitions. Additionally, he is co-author of Ernst & Young?s 12th ? 15th Biotechnology Industry Report and is a frequent and well respected speaker on industry matters. Scott is Ernst & Young?s liaison with ABFO, a trade organization for bioscience financial officers. He is also a former chairman and current treasurer of the Bay Area Bioscience Center (BayBio), a founding board member of the Biotechnology Institute and a member on the Biotechnology Industry Organizations (BIO) ECS board (until 2005). He is also a member of the board of the Leukemia and Lymphoma Society of America (Silicon Valley Chapter). Scott is a third generation San Franciscan and resides in the Bay Area with his wife, Jennifer, and sons, Christopher and Ryan.